Psilocybin

Psilocybin mushrooms, commonly known as magic mushrooms, are a polyphyletic informal group of fungi that contain psilocybin which turns into psilocin upon ingestion.

Read more in the app

Psilocybin generates psychedelic experience by disrupting brain network - EurekAlert

Psilocybin desynchronizes the human brain (2024)

Psilocybin generates psychedelic experience by disrupting brain network

Your brain on shrooms — how psilocybin resets neural networks. The psychedelic drug causes changes that last weeks to the communication pathways that connect distinct brain regions.

Psilocybin temporarily dissolves brain networks

Magic Mushrooms and the Mind: Psilocybin’s Hyperconnected Brain State Linked to Therapeutic Effects

How cannabis and psilocybin might help some of the 50 million Americans who are experiencing chronic pain

Decoding Psilocybin: “Magical” Enzymatic Pathways to Psychiatric Breakthroughs

Transforming Lives: Psilocybin’s Remarkable Effect on Cancer-Related Depression

Exploring the Impact of Psilocybin on the Immune System: Insights from a Controlled Study on Healthy Participants

Psilocybin-Assisted Therapy for Depression: A review and meta-Analysis finds psilocybin to have a significantly greater antidepressant effect compared to the placebo drug used. Response and remission rates also favoured participants who received psilocybin.

MDMA, Psilocybin, And Ketamine: 3 Psychedelics With Different Mental Health ‘Use Cases’

Religious leaders given psilocybin say they "felt God"

A study found that "three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning."

MDMA, Psilocybin Authorized as Medicines in Australia

Australia Legalizes Psilocybin And MDMA Prescriptions As U.S. Patients Seek Similar Authorization

MDMA and Psilocybin Are Approved as Medicines for the First Time

Restrictions on Psilocybin 'Magic Mushrooms' Are Easing as Research Ramps Up

Self-administration of Psilocybin in the Setting of Treatment-Resistant Depression (TRD): Microdosing with the Fadiman Protocol (12 min read) | Innovations in Clinical Neuroscience [Jul 2022]

Promising results from psilocybin trial for treatment-resistant depression